Results 111 to 120 of about 11,407 (242)
BIOLOGICALS AND BIOSIMILARS: AN OVERVIEW
, 2018 Biologics are highly sensitive large molecules with complex structure, difficult to characterize and reproduce, derived from living cells; used for treatment, diagnosis or prevention of disease. .
K. Ravi Shankar and K.P.R. Chowdary
core +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra +4 more
wiley +1 more source
Biosimilars, a rapidly growing category of medications in The United States of America (US), play a vital role in addressing health conditions. This study provides a comprehensive overview of the distinctions between Biosimilars and Generics, examining ...
AMOL MANDHARE (18275845)
core +1 more source
Medical specialists' attitudes to prescribing biosimilars
, 2017 Biosimilars are a cost-effective alternative to biologics that could improve patients' access to expensive biological medicines. Currently, there are little data on doctors' perceptions of biosimilars and in what situations they are comfortable ...
Amy Hemmington +13 more
core +1 more source
ФармакоэкономикаBackground. The increasing number of registered biosimilars of monoclonal antibodies (mAbs) is altering the structure of the pharmaceutical market by amplifying the share of domestic manufacturers.
A. Yu. Efremov +5 more
doaj +1 more source
Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles
European Journal of Immunology, Volume 56, Issue 6, June 2026.Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes +2 more
wiley +1 more source
Patient attitudes and understanding about biosimilars: an international cross-sectional survey
, 2016 Ira Jacobs,1 Ena Singh,2 K Lea Sewell,3 Ahmad AL-Sabbagh,1 Lesley G Shane1 1Global Established Pharma Medicines Development Group, Pfizer Inc., New York, NY, 2Global Medical Affairs, Pfizer Inc., Collegeville, PA, 3Biotechnology Clinical Development ...
Jacobs I +4 more
core
Frontiers in Public HealthBackgroundAs China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern.
Xin Du +12 more
doaj +1 more source
Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics /
Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products.
Herzyk, Danuta J.,editor. +1 more
core
, 2015 Biosimilars are surmounting pharmaceutical market from last three decades and sale increasing progressively. Advances in the biotechnologylead to development and discovery of new biological products to treat various life-threatening diseases. Biosimilars
Prithvi, Shruthi D +2 more
core